Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 1, 2001, Pages 142-148

  Collet, J P ^a,b   Montalescot, G ^e   Lesty, C ^a   Soria, J ^b   Mishal, Z ^c   Thomas, D ^a   Soria, C ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e Centre Hospitalier Universitaire Pitié Salpêtrière ^*

Author keywords

Fibrinolysis; Glycoprotein IIb IIIa inhibitors; Platelets B fibrin

Indexed keywords

ABCIXIMAB; LYSINE ACETYLSALICYLATE;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CYTOARCHITECTURE; DRUG EFFECT; FIBRIN FORMATION; FIBRIN METABOLISM; FIBRINOLYSIS; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; THROMBOCYTE AGGREGATION; VISCOELASTICITY;

EID: 0035162774     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.1.142     Document Type: Article

References (33)

1. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without plasminogen activators
2. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: The ADMIRAL Study, 30-day final results
3. Randomized, placebocontrolled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction: ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators
4. Abciximab facilitates the rate and extent of thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial
5. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
6. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity
7. A torsion pendulum for measurement of the viscoelasticity of biopolymers and its application to actin networks
8. Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation
9. The morphological approach to segmentation: The watershed transformation
10. Early events in the plasmin digestion of fibrinogen and fibrin: Effects of plasmin on fibrin polymerization
11. Enzyme-mediated proteolysis of fibrous biopolymers: Dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport
12. Engineering design of optimal strategies for blood clot dissolution
13. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina
14. Pharmacodynamic study of (Fab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with, unstable angina
15. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade
16. Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development
17. Dissecting clot retraction and platelet aggregation
18. The contribution of the three hypothesized integrin-binding sites in fibrinogen to platelet-mediated clot retraction
19. Glycoprotein IIb/IIIa blockade inhibits platelet-mediated force development and reducts gel elastic modulus
20. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: A possible explanation for resistance to coronary/thrombolysis
21. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction
22. Measurement of platelet mediated force development during plasma clot formation
23. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
24. Inhibition of platelet-mediated, tissue-factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis."
25. Predictors of coronary reflow with intravenous chimeric 7E3 antibody in acute myocardial infarction
26. Dynamic coagulation studies: Influence of normal and abnormal platelets on clot structure formation
27. Regulation of fibrinolysis by platelet released plasminogen activator inhibitor 1: Light scattering and ultrastructural examination of lysis of a model platelet fibrin thrombus
28. Uncoping fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface
29. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
30. Ultrastructural analysis of thrombolysis by streptokinase and tissue-type plasminogen activator of experimental coronary artery thrombosis
31. Flow through clots determines the rate and pattern of fibrinolysis
32. Finger-like lysing patterns of blood clots